News Column

Researchers from University of Texas Report on Findings in Immunotherapy

May 26, 2014



By a News Reporter-Staff News Editor at Cancer Vaccine Week -- A new study on Biotechnology is now available. According to news reporting originating from Houston, Texas, by NewsRx correspondents, research stated, "The mTOR inhibitor, everolimus, is approved for the treatment of metastatic renal cell carcinoma (RCC). However, prognostic models are needed to determine the patients who would most benefit from this therapy."

Our news editors obtained a quote from the research from the University of Texas, "We have developed a model based on clinical parameters and patient stratification into risk groups to predict patients with RCC who will derive the most benefit from treatment with everolimus. We assessed retrospective data on 57 patients with RCC who received everolimus after previous treatment with immunotherapy or tyrosine kinase inhibitors to identify prognostic factors for progression-free survival (PFS) and overall survival (OS). In the original phase H study, patients received 10 mg of everolimus daily without interruption and were assessed every other week for the first 8 weeks on therapy and every 4 weeks thereafter. Kaplan-Meier analysis was used to calculate OS and PFS. Univariate and multivariate analyses were constructed using the Cox proportional hazards model and a stepwise procedure to validate the data Results: We grouped patients according to risk: 0 prognostic factors indicated favorable risk, 1 to 2 factors intermediate risk, and >= 3 factors poor risk. We found notable differences in median OS (29.6 mo for favorable risk, 14.3 mo for intermediate risk, and 7.2 mo for poor risk). Three risk factors (prior radiation treatment, no lung metastasis present at the start of treatment, and lymphocytes < 25 cells/mu l) in the multivariate analysis were found to be associated with PFS, and 4 risk factors were found to be associated with OS (bone metastasis at start of treatment, LDH > 1.5 x upper limit of normal, alkaline phosphatase > 120 U/l, and lymphocytes < 25 cells/A. Our prognostic model includes 3 readily available clinical parameters for PFS and 4 readily available clinical parameters for OS to help stratify patients into poor, intermediate, and favorable prognosis groups for the treatment of everolimus in clear cell RCC."

According to the news editors, the research concluded: "These intriguing results warrant further study in a larger patient population to validate the findings."

For more information on this research see: Clinical prognostic factors associated with outcome in patients with renal cell cancer with prior tyrosine kinase inhibitors or immunotherapy treated with everolimus. Urologic Oncology-Seminars and Original Investigations, 2014;32(3):345-354. Urologic Oncology-Seminars and Original Investigations can be contacted at: Elsevier Science Inc, 360 Park Ave South, New York, NY 10010-1710, USA (see also Biotechnology).

The news editors report that additional information may be obtained by contacting R.J. Amato, Univ Texas Houston, Sch Public Hlth, Houston, TX, United States. Additional authors for this research include A. Flaherty, Y.F. Zhang, F.Q. Ouyang and V. Mohlere.

Keywords for this news article include: Biotechnology, Texas, Cancer, Kidney, Houston, Oncology, Proteins, Immunology, Nephrology, Proteomics, Blood Cells, Lymphocytes, United States, Immunotherapy, Tyrosine Kinase, Immunomodulation, Risk and Prevention, Aromatic Amino Acids, Renal Cell Carcinoma, Enzymes and Coenzymes, Mononuclear Leukocytes

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Cancer Vaccine Week